Cancer
Cancer Ongoing 2021 NSW, QLD, SA, VIC, WA

DCISionRT® Registry

Prospective Registry to Evaluate the Effect of the DCISionRT® Test on Treatment Decisions in Patients with Ductal Carcinoma In Situ (DCIS) Following Breast Conserving Therapy.

Trial overview

Disease
Breast cancer
Topic
DCISionRT® Registry
Eligibility criteria

To be considered for this registry you must meet the following criteria:

  • Have histologically confirmed ductal carcinoma in situ (DCIS) in a single breast (presence of lobular carcinoma in situ (LCIS) or other benign breast disease in addition to DCIS is acceptable).
  • Have the DCISionRT test ordered during routine patient care.
  • Planning to undergo breast conserving surgery.
  • Eligible to receive radiation and/or systemic treatment
Study details

Your participation in this registry means information will be collected about your diagnosis, test result (which will be shared with your doctor and radiation oncologist), treatment and outcomes over a 5-year period.  In addition, your de-identified results could be used for future medical research by PreludeDx and GenesisCare. Such research may involve the investigation of new methods of diagnosis and treatment, the development of new products, treatment pathways and patient management processes.

More information

For more information about DCISionRT® click here.

Phone: 1300 086 870

Email:

 

Location

NSW, QLD, SA, VIC, WA